ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1699

Endothelial and Platelet Microparticles As Potential Novel Biomarkers of Peripheral Microvascular Dysfunction in Systemic Sclerosis and Primary Raynaud’s Phenomenon

John D. Pauling1,2, Daniel Moreno-Martinez3, Fiona Wilkinson4, Ben Parker5,6, Jacqueline A. Shipley1, Darren Hart1, Neil J McHugh1,2 and Yvonne Alexander3, 1Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, 3Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, 4School of Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom, 5Institute of Inflammation and Repair School of Translation Medicine The University of Manchester, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 6Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biomarkers, imaging techniques, microparticles and systemic sclerosis, Raynaud's phenomenon

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics: Systemic Sclerosis, Diagnostic and Therapeutic Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose

Microparticles (MPs) are membrane-bound vesicles derived from vascular and intravascular cells such as endothelial cells (EMPs) and platelets (PMPs). MPs form during cell activation or apoptosis and may directly contribute to disease pathogenesis. Circulating MPs have been found to be higher in systemic sclerosis (SSc) compared with healthy controls, however their precise functional role remains to be elucidated. The present study was undertaken to establish whether plasma MP levels differ between primary Raynaud’s phenomenon (RP) and SSc and whether EMP and PMP levels correlate with dynamic assessment of digital microvascular function assessed using laser speckle contrast imaging (LSCI).

Methods

Patients with SSc (n=24, 22 with limited cutaneous SSc) and primary RP (n=16) not taking anti-platelet agents, NSAIDs or steroids were recruited to the study. Platelet-free plasma was obtained using citrated blood following a 2-step centrifugation regime. Digital perfusion at the volar aspect of the distal left middle finger was assessed using LSCI during a standardised local cold challenge (15°C for 60s). Digital perfusion was assessed at baseline, immediately following cold challenge (t0) and at 5 minute intervals during re-perfusion (t5, t10 and t15 respectively). Plasma levels of EMPs (AnnexinV+/CD31+/CD42b-) and PMPs (AnnexinV+/CD31+/CD42b+ or AnnexinV+/CD31-/CD42b+) were quantified using flow cytometry.

Results

Plasma levels of EMPs (161271/ml vs. 171318/ml) and PMPs (186348/ml vs. 246758/ml) did not differ between SSc and primary RP. Higher EMP levels were found in patients with SSc and a history of digital ulceration (DU) or digital pitting (DP) (median 198643/ml vs. 144840/ml, p=0.03). No additional associations between MP levels and disease characteristics were identified. Consistent positive correlations between MP levels and digital perfusion following cold challenge (but not at baseline) were identified in SSc (Table). In contrast, there were consistent negative correlations between PMP (but not EMP) levels and digital perfusion at both baseline and following cold challenge in primary RP (Table).

Conclusion

This is the first study to explore the relationship between circulating MP levels and peripheral microvascular dysfunction in primary RP and SSc. Higher EMPs were associated with a history of DU/DP in SSc. Higher EMP and PMP levels, however, were associated with higher digital perfusion following local cold challenge in SSc. In contrast, higher PMP levels were associated with lower digital perfusion in primary RP. There was no association between EMP levels and digital perfusion in primary RP. Additional work is needed to explore factors leading to MP generation and their contribution to peripheral microvascular dysfunction in primary RP and SSc. MPs may have the potential to act as biomarkers of peripheral microvascular dysfunction/damage in primary RP and SSc.

Table

 

 

 

Baseline

t0

t5

t10

t15

SSc

EMPs

Spearman’s rho

p value

0.05

0.821

0.42

0.044

0.42

0.043

0.46

0.026

0.46

0.025

PMPs

Spearman’s rho

p value

0.19

0.377

0.42

0.047

0.52

0.009

0.54

0.006

0.64

0.001

Primary RP

EMPs

Spearman’s rho

p value

-0.34

0.149

-0.33

0.20

-0.13

0.648

-0.39

0.131

0.09

0.753

PMPs

Spearman’s rho

p value

-0.52

0.041

-0.33

0.232

-0.69

0.003

-0.65

0.006

-0.49

0.057

 


Disclosure:

J. D. Pauling,
None;

D. Moreno-Martinez,
None;

F. Wilkinson,
None;

B. Parker,
None;

J. A. Shipley,
None;

D. Hart,
None;

N. J. McHugh,
None;

Y. Alexander,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/endothelial-and-platelet-microparticles-as-potential-novel-biomarkers-of-peripheral-microvascular-dysfunction-in-systemic-sclerosis-and-primary-raynauds-phenomenon/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology